Amber Rogers

ORCID: 0000-0002-7071-7889
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Immunotherapy and Biomarkers
  • Cell Adhesion Molecules Research
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • 14-3-3 protein interactions
  • Kruppel-like factors research
  • vaccines and immunoinformatics approaches
  • Caveolin-1 and cellular processes
  • Inflammation biomarkers and pathways
  • Epigenetics and DNA Methylation
  • Bone Metabolism and Diseases
  • Monoclonal and Polyclonal Antibodies Research
  • Apelin-related biomedical research
  • Ubiquitin and proteasome pathways
  • Reproductive Biology and Fertility
  • Cancer Cells and Metastasis
  • Immune Cell Function and Interaction
  • Renal and related cancers

CRUK Lung Cancer Centre of Excellence
2023-2025

University College London
2023-2025

London Cancer
2025

Indiana University – Purdue University Indianapolis
2024

Indiana University School of Medicine
2024

Indiana University
2024

University of Indianapolis
2024

University School
2024

Cardiff University
2023

The T cells of the immune system can target tumors and clear solid cancers following tumor-infiltrating lymphocyte (TIL) therapy. We used combinatorial peptide libraries a proteomic database to reveal antigen specificities persistent cancer-specific cell receptors (TCRs) successful TIL therapy for stage IV malignant melanoma. Remarkably, individual TCRs could multiple different tumor types via HLA A∗02:01-restricted epitopes EAAGIGILTV, LLLGIGILVL, NLSALGIFST from Melan A, BST2, IMP2,...

10.1016/j.cell.2023.06.020 article EN cc-by Cell 2023-07-24

Abstract Neoantigen vaccines are under investigation for various cancers, including epidermal growth factor receptor ( EGFR )-driven lung cancers 1,2 . We tracked the phylogenetic history of an mutant cancer treated with erlotinib, osimertinib, radiotherapy and a personalized neopeptide vaccine (NPV) targeting ten somatic mutations, exon 19 deletion (ex19del). The ex19del mutation was clonal, but is likely to have appeared after whole-genome doubling (WGD) event. Following osimertinib NPV...

10.1038/s41586-025-08586-y article EN cc-by Nature 2025-02-19

Protamines (PRM1 and PRM2) are small, arginine-rich, nuclear proteins that replace histones in the final stages of spermiogenesis, ensuring chromatin compaction remodeling. Defects protamination lead to increased DNA fragmentation reduced male fertility. Since efficient sperm production requires translocation protamines from cytoplasm nucleus, we investigated whether SPAG17, a protein crucial for intracellular trafficking during participates protamine transport. Initially, assessed...

10.3389/fcell.2023.1125096 article EN cc-by Frontiers in Cell and Developmental Biology 2023-09-12

Abstract Background Platinum-based chemotherapy regimens are a mainstay in the management of ovarian cancer (OC), but emergence chemoresistance poses significant clinical challenge. The persistence stem cells (OCSCs) at end primary treatment contributes to disease recurrence. Here, we hypothesized that extracellular matrix protects CSCs during and supports their tumorigenic functions by activating integrin-linked kinase (ILK), key enzyme drug resistance. Methods TCGA datasets OC models were...

10.1186/s13046-024-03083-y article EN cc-by Journal of Experimental & Clinical Cancer Research 2024-06-01

Abstract Background: Effective treatment of ovarian cancer (OC) is greatly impacted by advanced, late-stage diagnosis which usually presents with intra-peritoneal metastases, chemoresistance and high recurrence. The development metastases correlated the formation multicellular spheroids disseminated in peritoneal fluid. Spheroid promoted a change cell adhesion properties, enhanced secretion extracellular matrix (ECM) components that stiffen tumor stroma promote aberrant activation oncogenic...

10.1158/1538-7445.ovarian23-b095 article EN Cancer Research 2024-03-04

<title>Abstract</title> Background Platinum-based chemotherapy regimens are a mainstay in the management of ovarian cancer (OC), but emergence chemoresistance poses significant clinical challenge. The persistence stem cells (OCSCs) at end primary treatment contributes to disease recurrence. Here, we hypothesized that extracellular matrix protects CSCs during and supports their tumorigenic functions by activating integrin-linked kinase (ILK), key enzyme drug resistance. Methods TCGA datasets...

10.21203/rs.3.rs-4086737/v1 preprint EN cc-by Research Square (Research Square) 2024-03-13

Abstract The R47H variant of the triggering receptor expressed on myeloid cells 2 (TREM2) is a risk factor for Alzheimer’s disease in humans and leads to lower bone mass accrual female but not male 12-mo-old mice. To determine whether, as with aging, gonadectomy results sex-specific musculoskeletal effects, gonad removal or SHAM surgery was performed 4-mo-old TREM2R47H/+ mice WT littermates (n = 10-12/group), sexes analyzed separately. Body weight males, higher females after gonadectomy,...

10.1093/jbmrpl/ziae144 article EN cc-by JBMR Plus 2024-11-13

<h3>Background</h3> Advanced lung cancer kills 90% of patients within a decade, underscoring an urgent need for improved early detection and prevention technologies. T cell responses are initiated dysregulated during carcinogenesis <i>in vivo</i>, providing potential basis immune-focused interception. Here we examined cross-tissue dynamics human murine squamous to assess their utility in immune-interception. <h3>Methods</h3> Over decade ago clinical autofluorescence bronchoscopy surveillance...

10.1136/jitc-2023-sitc2023.1032 article EN cc-by-nc Regular and Young Investigator Award Abstracts 2023-10-31

<h3>Background</h3> Adoptive transfer of ex-vivo expanded tumor-infiltrating lymphocytes (TIL) has shown promise in the clinic. However, non-specific expansion TIL and lack understanding active component resulted poor correlation between clinical response dose as well resistance mechanisms. The VELOS<sup>TM</sup> manufacturing process generates a precision personalized treatment modality by targeting clonal neoantigens with incorporation an antigen-specific step to enrich product for these...

10.1136/jitc-2021-sitc2021.193 article EN Regular and Young Investigator Award Abstracts 2021-11-01
Coming Soon ...